AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012
This article was originally published in The Pink Sheet Daily
The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.
You may also be interested in...
Soriot Makes Changes At AstraZeneca As The Pharma Explores Its Options
AstraZeneca’s Soriot makes big moves on his first day on the job – putting a hold on the company’s share-repurchase program and causing speculation that a big acquisition is set for the near future.
Brennan’s Abrupt Departure Has Some Viewing AstraZeneca As A Buyout Target
A rough first quarter and news of the CEO’s decision to step down in slightly over a month leads to speculation that AstraZeneca could be an attractive M&A target for another pharma that might shut down the company’s struggling R&D effort and cash in on the existing portfolio.
We’re #8! PTO Ranks The Economic Power Of Pharma’s Patents
Pharmaceuticals falls below computers, communications and electrical equipment in “patent intensity” – the ratio of patents to jobs – according to a Patent and Trademark Office report on the importance of intellectual property to the U.S. economy.